In addition, the side-effect and toxicity profile (19% of cutaneous squamous cell carcinoma in BRAF inhibitor arm vs. 7% in the combination arm in melanoma patients) favors the combination therapy [12]. This evidence concerns the gene BRAF and cutaneous squamous cell carcinoma.